|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Olmesartan medoxornil:influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil显示文摘 | Bergmann K Laeis P Puchler K | 2001 | J Hypertens2001，19，1： | 1 |
| 2 | Clinical efficacy of olesartan medoxomil显示文摘 | Brunner H R Laeis P T | 2004 | J Hypert2004，21，2： | 1 |
| 3 | Effects of fluticasone on systemie maskers of inflammation in chronic obstructive pulmonary disease 显示文摘 | Sin DD Laey P York E | 2004 | Am J Respir Crit Care Med2004，170，7： | 1 |
| 4 | The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction 显示文摘 | Laeis P Puchler K Kirch W | 2001 | J Hypertens2001，19，1： | 1 |
| 5 | Rapid recovery of night blindness due to obesity surgery after vitamin A repletion therapy显示文摘 | SPITS Y DE LAEY J J LEROY B P | 2004 | Br J Ophthalmol2004，88，4： | 1 |
| 6 | Blood pressure and endocrine effects of single doses CS-866,a novel angiotensin Ⅱ antagonist,in sahrestrlcted hypertensive patients显示文摘 | Puchler K Nussberger J Laeis P | 1997 | J Hypertens1997，15，122： | 1 |
| 7 | The effect of an magnesium hydroxide) on the pharmacokinetics and safety of the oral angiotensin Ⅱ antagonist CS-866 in healthy male subjects 显示文摘 | Kawaratani T Laeis P Puchler K | 1999 | J Hypertens1999，17，3： | 1 |
| 8 | Clinical efficacy of olmesartan medoxomil显示文摘 | BrunnerHR Laeis P | 2003 | J Hypertens2003，21，2： | 1 |
| 9 | Olmesartan medoxomil:Influence of age,renal and hepatic function on the pharmacokinetics of Olmesartan medoxomil显示文摘 | Von Bergmann K Laeis P Puchler K | 2001 | J Hypertens2001，19，1： | 1 |
| 10 | The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction显示文摘 | Laeis P Puchler K Kiech W | 2001 | J Hypertens2001，19，： | 1 |
| 11 | Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin Ⅱ antagonist, in salt-restricted hypertensive patients显示文摘 | PUCHLER K NUSSBERGER J LAEIS P | 1997 | J Hypertens1997，15，122： | 1 |
| 12 | Blood pressure response, but not adverse event incidence, correlates with dose of angiotension Ⅱ antagonist显示文摘 | Puchler K Laeis P Stumpe KO | 2001 | J Hypertens2001，19，1： | 1 |
| 13 | Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil 显示文摘 | yon BERGMANN K LAEIS P PUCHLER K | 2001 | J Hypertens Suppl2001，191，： | 1 |
| 14 | The pharmacokinetic and metabolie profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction显示文摘 | Laeis P Puchler K Kirch W | 2001 | J Hypertens2001，19，1： | 1 |
| 15 | The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction显示文摘 | Laeis P Piichler K Kirch W | 2001 | J Hypertens Sup- pl2001，19，1： | 1 |
| 16 | Olmesartan me- doxomil :influence of age,renal and hepatic function on the pharmacokinetics of olmesartan medoxomil显示文摘 | von Bergmann K Laeis P Piichler K et d | 2001 | J Hyper- tens Supp12001，19，1： | 1 |
| 17 | Clinical efficacy of olmesartan me-doxomil显示文摘 | Brunner H R Laeis P | | 0，，02： | 1 |
| 18 | Clinical efficacy of olmesartan medoxomil 显示文摘 | Brunner HR Laeis P | 2003 | J Hypertens2003，21，2： | 1 |
| 19 | The pharmacokinetic metabohc profile Of Olmesartan medoxomil limits the risk of clinically relevant druginteraction显示文摘 | Puchler K KirCh W | 2001 | J Hypertens2001，19，2： | 1 |
| 20 | The effect of an antacid (aluminum magnesium hydroxide) on the pharmaeokinetics and safety of the oral angio- tensin Ⅱ antagonist CS 866 in healthy male subjects 显示文摘 | Kawaratani T Laeis P Ptichler K | 1999 | J Hypertens1999，17，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员